All In MedTech

Device Trial Radar · NCT07764146

An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease

An Open Label Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of VY1706 in Participants With Early Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Sep 3, 2026

Primary completion

Apr 28, 2029

Study completion Apr 28, 2029

Sponsor

Lead sponsor
Voyager TherapeuticsNot on our public-company list
Sponsor type
Industry
First posted
Aug 13, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study

Conditions

  • Alzheimer s Disease

Interventions

  • VY1706 Low doseDrug

    Low dose

  • VY1706 Mid doseDrug

    Mid Dose

  • VY1706 High DoseDrug

    High dose

  • Anti-AAV9 Total Antibody (TAb) AssayDevice

    Anti-AAV9 Total Antibody (TAb) Assay

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To characterize the safety and tolerability in participants with AD by Incidence of treatment emergent adverse events, changes from baseline in vital signs, physical and neurological exams and other safety measuresTime frame: 52 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • K2 Medical Research, LLC

    Maitland, Florida · Recruiting

  • AdventHealth Orlando

    Orlando, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.